Nearly Doubling of Survival Rates in Myeloma Patients Since 2005

Recent research conducted by the University of York reveals a significant improvement in the survival outlook for individuals diagnosed with multiple myeloma, one of the most prevalent blood cancers. The study indicates that the median survival time for myeloma patients has nearly doubled over the past decade and a half, increasing from approximately 2.4 years in 2005 to about 4.5 years in 2019. This encouraging trend is based on data collected from more than 3,700 patients in England and underscores the impact of advancements in treatment options.

Historically, myeloma has been associated with low survival rates, primarily due to limited effective therapies. However, recent innovations, such as targeted drugs like bortezomib—which offers fewer side effects compared to traditional chemotherapy—have played a crucial role in improving patient outcomes. Notably, the most substantial gains have been observed among older patients aged 80 and above, with survival rates for this age group increasing fivefold since 2005. Increased participation in clinical trials and the availability of gentler, more tolerable treatments for frail patients contribute to this progress.

The findings were published during Blood Cancer Awareness Month and highlight that while survival has improved, myeloma remains a challenging disease with no current cure. Blood Cancer UK reports that around 6,300 people are diagnosed with myeloma annually in the UK, accounting for about 2% of all cancers. Experts emphasize the importance of continued research and innovation to further extend survival and improve quality of life for those affected.

Prominent voices in the healthcare community, including Professor Alexandra Smith, and organizations like Cancer Research UK and Blood Cancer UK, stress that sustained efforts are essential. They advocate for increased access to clinical trials and faster implementation of new treatments. The Centre for Blood Research and the Haematological Malignancy Research Network at the University of York continue to play vital roles in understanding blood cancers and developing more effective therapies, aiming to turn these survival gains into cures in the future.